Marijuana for PTSD: Existing Evidence and MAPS' FDA-Approved Protocol - Sue Sisley

Dr. Sue Sisley details the regulatory hurdles involved in conducting FDA-approved clinical research on cannabis for veteran treatment-resistant PTSD. The research faces a government-enforced monopoly maintained by the National Institute on Drug Abuse (NIDA), which limits the supply and quality of cannabis available to researchers and maintains an opaque timeline for study protocol reviews compared to other substance research. Contrasting the scheduling of cannabis with other substances, this presentation highlights the administrative inconsistencies that impede medical research. Clinical study protocols for PTSD treatment are in development, emphasizing safety measures, dose titration, and the potential efficacy of different delivery methods like vaporizers for treating symptom clusters in combat veterans.